Skip to content

Vedolizumab fixed clearance and exposure contexts

Eight supplied linear two-compartment PK contexts with fixed prior-treatment coefficient indicators, complete central infusion histories, concentration AUC and explicit physical drug accounting.

Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics ↗

Pharmaceutics

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does the induction schedule change vedolizumab accumulation?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Fixed typical PK · 10w q4w · prior history 0

Fixed two-compartment serum PK under the complete supplied infusion calendar and one binary prior-treatment coefficient context. No posterior cohort or remission outcome is simulated.

0–630 day

Scenario details

Fixed typical PK · 10w q4w · prior history 0

Fixed two-compartment serum PK under the complete supplied infusion calendar and one binary prior-treatment coefficient context. No posterior cohort or remission outcome is simulated.

Readouts

C central · ug/mL
Fixed deterministic PK coordinate; no clinical or population outcome prediction.
AUC central · ug*day/mL
Exact numeric unit alias: mg·day/L equals µg·day/mL; not an independent endpoint.
Effective clearance · L/day
Fixed deterministic PK coordinate; no clinical or population outcome prediction.
Accounted drug · mg
Current plus eliminated drug; equals cumulative delivered infusion mass

Study purpose

  • How do the model's key biological readouts change under fixed typical pk · 10w q4w · prior history 0?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
630 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Eight supplied linear two-compartment PK contexts with fixed prior-treatment coefficient indicators, complete central infusion histories, concentration AUC and explicit physical drug accounting.

Eight supplied linear two-compartment PK contexts with fixed prior-treatment coefficient indicators, complete central infusion histories, concentration AUC and explicit physical drug accounting.

Model details

6 parameters · 5 states · 5 equations · 25 derived outputs

Classification & API access
Therapeutic
Vedolizumab
Modality
Monoclonal antibody
Target
Integrin α4β7
Disease / scope
Inflammatory bowel disease
ParameterDefaultUnitDescription
Anti-TNF effectATNF_effect0.264—Fixed supplied Table 2 typical coefficient or binary prior-treatment context; no population draw or editable domain.
Systemic clearanceCL_L_day0.159L/dayFixed supplied Table 2 typical coefficient or binary prior-treatment context; no population draw or editable domain.
Intercompartmental clearanceQ_L_day0.12L/dayFixed supplied Table 2 typical coefficient or binary prior-treatment context; no population draw or editable domain.
Central distribution volumeVc_L3.19LFixed supplied Table 2 typical coefficient or binary prior-treatment context; no population draw or editable domain.
Peripheral distribution volumeVp_L1.66LFixed supplied Table 2 typical coefficient or binary prior-treatment context; no population draw or editable domain.
Prior anti tnfprior_anti_tnf0—Fixed supplied Table 2 typical coefficient or binary prior-treatment context; no population draw or editable domain.

Related models

Dupilumab exposure and atopic-dermatitis responseEculizumab fixed PK and authored response diagnosticsPertuzumab fixed serum PK contextsAtezolizumab PK: baseline patient profiles

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics